| Literature DB >> 28114277 |
C Hermanns1, V Hampl1, K Holzer2, A Aigner3, J Penkava1, N Frank1, D E Martin4, K C Maier4, N Waldburger2, S Roessler2, M Goppelt-Struebe5, I Akrap6, A Thavamani6, S Singer2, A Nordheim6,7, T Gudermann1, S Muehlich1.
Abstract
Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are transcriptional coactivators of Serum Response Factor (SRF) with an essential role for hepatocellular carcinoma (HCC) growth and oncogene-induced senescence. In this report, we identified myoferlin as a novel MKL/SRF target gene by gene expression profiling and verification in vivo in HCC xenografts. Myoferlin was overexpressed in human and murine HCCs triggered by conditional expression of constitutively active SRF-VP16 protein in hepatocytes. Furthermore, myoferlin was required for HCC cell invasion, proliferation and anchorage-independent cell growth. We provide evidence that myoferlin is a crucial gene target of MKL1/2 mediating its effect on oncogene-induced senescence by modulating the activation state of the EGFR and downstream MAPK and p16-/Rb pathways. Depletion of myoferlin in tumour cells from SRF-VP16-derived murine HCCs induced a senescence phenotype. These findings identify MKL1/2 and myoferlin as novel therapeutic targets to treat human HCC by a senescence-inducing strategy.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28114277 DOI: 10.1038/onc.2016.496
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867